These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18372573)

  • 21. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QT interval and drug therapy.
    Drug Ther Bull; 2016 Mar; 54(3):33-6. PubMed ID: 26966121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?
    Antzelevitch C
    J Electrocardiol; 2004; 37 Suppl():15-24. PubMed ID: 15534788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Electro-Mechanical window: a risk marker for Torsade de Pointes in a canine model of drug induced arrhythmias.
    van der Linde HJ; Van Deuren B; Somers Y; Loenders B; Towart R; Gallacher DJ
    Br J Pharmacol; 2010 Dec; 161(7):1444-54. PubMed ID: 21054337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
    Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
    J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced prolongation of the QT interval.
    Roden DM
    N Engl J Med; 2004 Mar; 350(10):1013-22. PubMed ID: 14999113
    [No Abstract]   [Full Text] [Related]  

  • 31. A 2015 focus on preventing drug-induced arrhythmias.
    Bossu A; van der Heyden MA; de Boer TP; Vos MA
    Expert Rev Cardiovasc Ther; 2016; 14(2):245-53. PubMed ID: 26560188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs, QT interval abnormalities and ventricular arrhythmias.
    Thomas SH
    Adverse Drug React Toxicol Rev; 1994; 13(2):77-102. PubMed ID: 7918900
    [No Abstract]   [Full Text] [Related]  

  • 33. Intracoronary acetylcholine-induced prolongation of the QT interval and Torsade des Pointes in long QT interval syndrome.
    Aizawa Y; Matsubara T; Higuchi K; Washizuka T; Tamura Y; Uchiyama H; Igarashi Y; Shibata A
    Jpn Heart J; 1994 Sep; 35(5):683-8. PubMed ID: 7830332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug-induced arrhythmias].
    Mizumaki K; Inoue H
    Nihon Rinsho; 2002 Jul; 60(7):1449-55. PubMed ID: 12136628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR
    Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-induced long QT and torsade de pointes: recent advances.
    Kannankeril PJ; Roden DM
    Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
    Guns PJ; Johnson DM; Weltens E; Lissens J
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.
    Champeroux P; Viaud K; El Amrani AI; Fowler JS; Martel E; Le Guennec JY; Richard S
    Br J Pharmacol; 2005 Feb; 144(3):376-85. PubMed ID: 15655517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.